FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
More and more data from preclinical and clinical studies strengthen the hypothesis that immune system-mediated actions contribute to and drive pathogenesis in Alzheimer’s disease. The team of Roosmarijn Vandenbroucke in the Claude Libert Group (VIB/UGent) combined their knowledge and expertise related to inflammation with the expertise in Alzheimer’s disease present in the Bart De Strooper Group (VIB/KU Leuven). This collaboration lead to the insights that Aβ indeed induces a strong inflammatory response, thereby destroying an important but often neglected brain barrier, called the blood-cerebrospinal fluid (CSF) barrier. Disruption of this blood-CSF barrier disturbs brain homeostasis and might negatively affect disease progression. Strikingly, these effects could be blocked in the presence of a matrix metalloproteinase (MMP) inhibitor. read more
Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces it has successfully raised €12 million in a Series B financing. The round was led by new investor Wales Life Sciences Fund. Current investors Vesalius Biocapital, LRM, PMV and Wyvern also participated in the round. Existing shareholders include the Wellcome Trust. Brenig Preest, Wales Life Sciences Fund, will join the Apitope board. read more
Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to start a further Phase II clinical trial with its lead product ATIR101™. In this new trial the safety and efficacy of using a second dose of ATIR101™ will be studied (NCT02500550 / EudraCT 2015-002821-20). read more
BELCHAM, De Belgisch-Amerikaanse Kamer van Koophandel, heeft in New York zijn jaarlijkse reeks prijzen uitgereikt. De Antwerpse longspecialist Fluidda werd bekroond als meest beloftevolle onderneming van het jaar. read more
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the initiation of a multinational, double-blind placebo-controlled Phase III "HERCULES" study evaluating efficacy and safety of caplacizumab, its wholly-owned anti-vWF Nanobody, in acquired TTP. The study is expected to enrol 92 patients at clinical sites across 17 countries. read more
Novosanis closed a new round of financing. The share capital was increased by a combined cash contribution from current investor Taste Invest and from the Novosanis management team. This new round brings the Flemish medical device company to a total in equity of 1.64M Eur. read more
Unlike ales, lager beers differ little in flavor. But now, by creating new crosses among the relevant yeasts, Kevin Verstrepen, Stijn Mertens and their collaborators at VIB/KU Leuven have opened up new horizons of taste. The research is published in the September 25 Applied and Environmental Microbiology, a journal of the American Society for Microbiology. read more
TiGenix announced a major breakthrough at the end of August. The recent Phase III trial for Cx601 was successfully completed, with a single injection of Cx601 healing complex fistulas in patients with Crohn's disease (an inflammatory disease of the intestine). And people said mergers don't work! With sales of ChondroCelect cartilage repair at a disappointing level, the Belgian company, TiGenix, merged with the Spanish Cellerix, which brought Cx601 into the marriage. Chances are now good that TiGenix will have a new drug on the market in a couple of years. . Above all, this is living proof of TiGenix's pioneering role in stem cell therapy: this is the first Phase III success for any allogeneic stem cell therapy everAn interview with Eduardo Bravo, the Spanish CEO of the merged company. read more
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces that it has treated the first patients suffering from a failed spinal fusion with its unique allogeneic bone cell therapy product ALLOB®. read more
Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the Company will be moving filgotinib, its highly selective JAK1 inhibitor, into Phase 3 in rheumatoid arthritis by early 2016. Filgotinib has shown best-in-class efficacy and safety in the DARWIN Phase 2B studies in rheumatoid arthritis and is now fully owned by Galapagos. read more